MedRhythms Selects Curavit as its Contract Research Organization (CRO) for a Chronic Stroke Decentralized Clinical Trial
NEW YORK, Sept. 20, 2023 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), announced that it was selected as the VCRO for a study of MR-001, MedRhythms' neurorehabilitation system designed to improve walking and ambulation in adults with chronic stroke walking impairments. The goal of the study is to further characterize the long-term economic and clinical benefits of MR-001 beyond what has been established in a multi-center, randomized clinical trial. This will also include evaluating patient engagement and therapeutic response durability.
- The goal of the study is to further characterize the long-term economic and clinical benefits of MR-001 beyond what has been established in a multi-center, randomized clinical trial.
- Curavit is responsible for managing all aspects of MedRhythms' hybrid decentralized clinical trial (DCT) – from protocol finalization and Institutional Review Board (IRB) approvals to patient recruitment, testing at physical sites, remote site and patient monitoring and healthcare economics and outcomes analysis.
- Health economics research quantifies the long-term financial impact for patients, providers, and payers," said Owen McCarthy, President and co-founder of MedRhythms.
- MR-001 is based on Rhythmic Auditory Stimulation (RAS), a clinical intervention utilizing the mechanism of auditory-motor entrainment ("entrainment").